CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION BOTH IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ** Technology Transfer AgreementTechnology Transfer Agreement • October 9th, 2020 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • Hong Kong
This Technology Transfer Agreement between Qualigen, Inc. (“Qualigen”), a legal entity incorporated in Delaware, USA, with its offices at 2042 Corte del Nogal, Suite B, Carlsbad, California 92011, USA; and Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (翊新诊断技术（苏州）有限公司) (“Licensee”), a legal entity registered in Room 301, 302, Building 9, No. 188 Fu Chung Jiang Lu, Suzhou High Technology Zone, Suzhou,（中国苏州富春江路188号9号楼301，302室）, the People’s Republic of China (individually “Party” and together “Parties”), is effective as of October 7, 2020 (“Effective Date”).
